Elan, Lonza in Supply Deal - Analyst Blog
05 Dicembre 2011 - 4:00PM
Zacks
Elan Corporation (ELN) recently announced that
it has entered into a manufacturing agreement with Lonza
Group AG (LZAGY). As per the agreement, Lonza will supply
the active pharmaceutical ingredient (API) of ELND005
(scyllo-inositol).
In December 2010, Elan had modified its agreement with
Transition Therapeutics Inc. (TTHI) following
Transition Therapeutics’ decision to exercise its opt-out right
under the original agreement. According to the modified agreement,
not only has Transition Therapeutics returned the 30% stake in
ELND005 to Elan, it will also no longer fund the development of
ELND005. Elan paid Transition Therapeutics $9 million in January
2011 and is obligated to pay an additional $11 million upon the
initiation of the next ELND005 study. However, Elan will no longer
pay the stipulated $25 million as a milestone payment on the
commencement of the phase III study for ELND005.
ELND005 is a small molecule beta amyloid anti-aggregation agent.
In August 2010, Elan and Transition Therapeutics had reported data
on ELND005 from a phase II study for Alzheimer’s disease. While the
study failed to achieve statistical significance for its co-primary
endpoints, the companies said that the safety and tolerability data
were encouraging. Elan will continue to pursue the development of
the candidate for Alzheimer’s.
Meanwhile, the company plans to evaluate ELND005 for other
indications such as bipolar disorder for which a proof of concept,
phase II study will be conducted. The agreement with Lonza will
help Elan ensure high quality supply of ELND005.
Our Recommendation
We currently have a Neutral recommendation on Elan. The stock
carries a Zacks #4 Rank (Sell rating) in the short run. The company
is highly dependent on Tysabri for revenue generation. In this
scenario, we note that an increase in the number of progressive
multifocal leukoencephalopathy (PML) cases associated with the use
of Tysabri could lead to a slowdown in the sales of the drug going
forward.
ELAN CP PLC ADR (ELN): Free Stock Analysis Report
TRANSITN THERAP (TTHI): Free Stock Analysis Report
Zacks Investment Research
Grafico Azioni Lonza (PK) (USOTC:LZAGY)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Lonza (PK) (USOTC:LZAGY)
Storico
Da Gen 2024 a Gen 2025
Notizie in Tempo Reale relative a Lonza Group AG (PK) (OTCMarkets): 0 articoli recenti
Più Lonza Group Unsp/adr (PC) Articoli Notizie